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Abstract 
Background: Increased toxicities have been identified with higher doses of pegaspargase 
(PEG-ASP) in adults. This has led to routine use of a 3,750 IU dose cap for adult acute 
lymphocytic leukemia (ALL) patients in most institutions. In pediatric ALL, PEG-ASP is not 
capped. There is concern at our institution that larger doses may result in increased rates of 
adverse effects and that increased monitoring may be warranted in pediatric patients 
receiving doses greater than 3,750 IU. The objective of this study is to quantify the difference 
in rates of PEG-ASP-associated adverse events between pediatric patients who received 
doses greater than 3,750 IU and 3,750 IU or less. 
 
Methods: Retrospective chart review of patients 1-21 years old with pre-B cell ALL who 
received PEG-ASP between 2007 and 2014 at an academic medical center. 
 
Results: Of 183 patients included in the analysis, 24 patients received PEG-ASP doses 
>3,750 IU and 159 patients received doses ≤3,750 IU. The incidence of VTE was 
significantly higher for patients in the >3,750 IU group compared to those who received 
≤3,750 IU, 20.8% vs. 1.89% respectively, p=0.0011. The incidence of pancreatitis 
(p=0.0306) and hyperglycemia (p=0.0089) were also higher in the >3,750 IU group. 
 
Conclusions: PEG-ASP doses >3,750 IU are associated with higher rates of VTE, 
pancreatitis, and hyperglycemia in pediatric patients with pre-B cell ALL. Patients receiving 
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>3,750 IU should have increased monitoring, and larger, multicenter trials are needed to 
determine if monitoring, VTE prophylaxis, and potential dose capping recommendations 
should be added to clinical trial protocols. 
 
 
 
Introduction 
Asparaginase formulations are a critical aspect of acute lymphoblastic leukemia 
(ALL) remission-induction treatment in both pediatric and adult populations. As part of an 
intensive, multi-agent chemotherapy regimen, asparaginase prolongs event- and disease-
free survival.1,2 Pegaspargase (Oncaspar®) is the current formulation of choice in most 
pediatric oncology clinical trials and protocols, as it was shown to be as effective as 
Escherichia coli asparaginase but with a prolonged duration of action.3 However, there are 
concerns regarding the toxicity profile of asparaginase formulations at higher doses. In 2007, 
the Cancer and Leukemia Group B (CALGB) study 9511 demonstrated that adult patients 
with ALL receiving pegaspargase (PEG-ASP) 2,000 IU/m2 with max dose 3,750 IU resulted 
in achieving effective asparagine depletion with improved disease free and overall survival.3,4 
Subsequent studies, including COG AALL0232 and CALGB 10403, used a dose of 2,500 
IU/m2 without a max dose and saw an increase in adverse events, specifically hepatotoxicity, 
during induction therapy.4,5 Therefore, many institutions, including our own, will cap PEG-
ASP dose at the single vial size, 3,750 IU, for adult patients.  
For pediatric patients, PEG-ASP 2,500 IU/m2 is typically used and there is no dose 
capping at 3,750 IU. Additionally, in some treatment regimens pediatric patients receive 
PEG-ASP as frequently as every 14 days, as opposed to adults who only receive PEG-ASP 
every 28 days.6 At our center, pediatric oncology practitioners have noted that patients 
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receiving doses greater than 3,750 IU experience increased rates of adverse drug events.  
To date there are currently no studies in the literature that illustrate a difference in the rates 
of adverse effects in children who receive PEG-ASP doses above or below 3,750 IU. 
Adverse effects associated with PEG-ASP include venous thromboembolism (VTE), 
coagulation disorders, pancreatitis, hypertriglyceridemia, hypersensitivity reactions, 
hyperglycemia, and increases in bilirubin and liver function tests.7,8,9 Given the known 
efficacy of PEG-ASP, this study aims to retrospectively compare the rates of adverse drug 
events in pediatric patients with B-cell ALL who receive >3,750 IU of PEG-ASP and ≤3,750 
IU of PEG-ASP in order to further elucidate the safety profile of PEG-ASP in a pediatric 
population.  The primary objective is to evaluate the hypothesis that use of doses greater 
than 3,750 units of PEG-ASP in pediatric oncology patients results in increased rates of 
adverse drug events. The secondary objective of this study is to assess the effect of doses 
>3,750 IU of PEG-ASP on treatment delays.  
 
Methods 
 
 We performed a retrospective cohort study of pediatric patients with ALL who 
received intramuscular (IM) or intravenous (IV) PEG-ASP at University of North Carolina 
(UNC) Medical Center in Chapel Hill, North Carolina. The Biomedical Institutional Review 
Board at UNC Medical Center approved this study. 
Patients were identified via the electronic medical record and were eligible for 
inclusion if they had pre-B-cell ALL and received PEG-ASP between January 1, 2007 and 
December 31, 2014. We identified 266 patients with ALL who received a total of 1,248 PEG-
ASP doses during this timeframe.  
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Demographics collected included patient’s sex, age, weight, body surface area 
(BSA), primary cancer diagnosis, comorbid conditions at time of PEG-ASP administration, 
along with date of disease relapse. Obesity and hyperglycemia were determined by 
diagnosis code and problem list. Parameters for PEG-ASP included dose(s), route and 
date(s) of administration, number of doses received, and adverse events potentially 
contributable to PEG-ASP occurring within 4 weeks of administration. The adverse effects 
reviewed were pancreatitis, hypertriglyceridemia, VTE, coagulation disorder, hyperglycemia, 
hypersensitivity, and elevated bilirubin and liver function tests. To assess the occurrence of 
these adverse events, the highest values of each of the following laboratory tests were 
collected: amylase, lipase, triglycerides, prothrombin time, D-dimer, total bilirubin, direct 
bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), and alkaline 
phosphatase (ALP). The lowest fibrinogen level within 4 weeks of PEG-ASP administration 
was also collected. Additionally, diagnosis codes and physician notes were utilized to identify 
adverse events not evident in the laboratory values.  
 
Statistical Analysis 
 Laboratory value analyses involved reducing the data to the most extreme recorded 
value for each category (i.e., the lowest for fibrinogen, and the highest for all others). 
Treatment delays were treated as binary variables (i.e., presence or absence of delays), and 
when analyzing treatment delays we included all observed doses and treated them as 
independent observations.  All continuous variables were analyzed using the Wilcoxon rank 
sum test. Fisher’s exact test was employed for binary variables. All reported p-values are 
two-sided.   
 
Results 
  
This article is protected by copyright. All rights reserved. 
8 
Patients 
In total, 266 pediatric patients with ALL were identified to have received a total of 
1,248 orders for PEG-ASP doses over the 8 year study period. We excluded 704 doses of 
PEG-ASP due to duplicate medication orders and diagnoses of NK-cell and T-cell ALL, thus 
leaving 544 doses from 189 patients for analysis. Among the 189 patients, 24 patients 
received PEG-ASP doses greater than 3,750 IU, 159 patients received doses less than or 
equal to 3,750 IU, and 6 patients were excluded from analyses because they received doses 
both above and below 3,750 IU. Therefore, the final analysis included 183 patients who 
received 523 PEG-ASP doses.  
Full details regarding the patient demographics are described in Table 1.  Some 
variation was noted in baseline characteristics between groups. Patients who received PEG-
ASP doses >3,750 IU were significantly older, had a significantly higher BSA and an 
increased presence of obesity than patients who received doses ≤3,750 IU.  
 
Primary Outcomes – Effect of Dosing on Asparaginase Related Toxicities 
Table 2 describes the primary outcome showing the incidence of treatment-related 
toxicities for the two dosing groups. As shown in the table, the incidence of VTE was 
significantly higher for patients in the >3,750 IU group compared to those who received 
≤3,750 IU, 20.8% vs. 1.9% respectively, p=0.001. Additionally, patients receiving >3,750 IU 
PEG-ASP developed pancreatitis more frequently (p=0.031). No difference was noted 
between groups regarding pulmonary embolism (PE) occurrences or the incidence of 
hypersensitivity reactions. Of the patients who experienced a VTE, only one patient in each 
group had a line-associated VTE. Detailed information about the patients who experienced 
VTE are shown in Table 3.  
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The majority of laboratory values did not differ significantly between the groups. 
Those labs that were statistically different included amylase, lipase, total and direct bilirubin, 
as well as ALT (Table 4).   
 
Secondary Outcomes – Effect of Dosing on Treatment Delays 
Table 5 summarizes the secondary outcome analysis. In the >3,750 IU group, 
patients experienced an increased incidence of treatment delays, however, this difference 
was not statistically significant (p=0.06). 
 
Discussion 
PEG-ASP has been shown to be effective in the treatment of pediatric ALL, as 
asparaginase formulations prolong event- and disease-free survival when added to intensive, 
multi-agent chemotherapy regimens.1,2  While CALGB caps adult doses of PEG-ASP at 
3,750 IU, the Children’s Oncology Group protocols currently do not dose cap for pediatric 
patients receiving PEG-ASP. To our knowledge, no studies have assessed the rates of 
PEG-ASP-associated adverse effects in pediatric patients receiving doses above 3,750 IU. 
The results of this study demonstrate that PEG-ASP doses greater than 3,750 IU are 
associated with a higher incidence of adverse effects including VTE, pancreatitis, and 
hyperglycemia. Notably, over 20% of patients that received >3,750 IU PEG-ASP 
experienced VTE compared to <2% of patients that received ≤3,750 IU PEG-ASP. Also, 
patients who experienced a VTE did not have severe hypertriglyceridemia (>1,000 mg/dL) 
which has been previously reported as a potential risk factor for VTE.8 Furthermore, it is 
standard practice for our group to a place single lumen port-a-cath in all patients upon 
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diagnosis.  Previous reports suggest that ports or internal lines are preferred as the risk of 
VTE is lesser than external central lines.10,11   Differences in the incidence of pancreatitis and 
hyperglycemia between the groups were also clinically relevant. The rate of pancreatitis in 
the >3,750 IU PEG-ASP group was over 6 times that of the ≤3,750 IU PEG-ASP group, and 
the rate of hyperglycemia was nearly 4 times as high in the >3,750 IU PEG-ASP group.  The 
difference in hyperglycemia incidence is difficult to explain, as all patients will receive either 
dexamethasone or prednisone during ALL remission-induction therapy. However, there have 
been previous reports of increased hyperglycemia incidence in patients who are greater than 
10 years old or overweight and these characteristics are more likely to be present in patients 
receiving PEG-ASP doses >3,750 IU.12    
There were many lab parameters that were significantly different between groups, 
including amylase, lipase, total bilirubin, and direct bilirubin. These differences are difficult to 
interpret as less than half of the patients in the study had a value obtained within four weeks 
of a PEG-ASP dose, which limits the external validity of the laboratory analysis. These 
results suggest the need for further evaluation of increased monitoring of specific lab 
parameters in pediatric patients receiving PEG-ASP.  
 Limitations of the study include the retrospective single-institution design, which does 
not allow for causality to be determined. However, the results outlined earlier identify a need 
for larger trials analyzing adverse effects of PEG-ASP doses greater than 3,750 IU in 
pediatric patients. Additionally, this study had a small number of patients who received 
doses greater than 3,750 IU and 95% (23/24) were greater than 10 years old. Older age may 
be a confounder given that in B-cell ALL, age greater than 10 years at diagnosis is 
associated with poorer disease outcomes. Given the small number of patients identified, 
outliers in the sample population also may skew results.  
 This study illustrates the safety concerns for pediatric patients receiving PEG-ASP 
>3,750 IU. In order to decrease the risks associated with PEG-ASP in pediatric patients, 
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increased monitoring for patients receiving doses >3,750 IU is an important first step. 
Additionally, with the vast majority of pediatric ALL patients treated on national clinical trial 
protocols, data on adverse effects related to PEG-ASP from large multi-center clinical trials 
should be collated to determine if increased monitoring, VTE prophylaxis, or dose capping at 
3,750 IU should be incorporated into these national protocols. Furthermore, recent data 
published on the use of asparaginase activity levels for therapeutic drug monitoring and 
PEG-ASP dose adjustments suggests that incorporation of asparaginase activity levels into 
upcoming treatment protocols might be one strategy available for reducing PEG-ASP dose-
related toxicities in the future.13,14 
 Overall, our study suggests pediatric patients experience serious adverse effects 
associated with PEG-ASP doses >3,750 IU. The most remarkable toxicity associated with 
higher doses of PEG-ASP was VTE, which occurred at an alarming rate of greater than 20% 
in the patients receiving >3,750 IU of PEG-ASP. This data suggests the need for increased 
monitoring in patients receiving PEG-ASP doses above 3,750 IU, and we hope that it 
prompts a larger analysis on this issue. Larger multicenter trials are needed to confirm the 
increased rates of PEG-ASP toxicities that were identified here. Subsequently, clinical trial 
protocols could be updated with increased monitoring, VTE prophylaxis, and potential dose 
capping recommendations. 
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TABLE 1 Demographics 
 ≤3,750 IU PEG-ASP 
n=159 
>3,750 IU PEG-ASP 
n=24 
P-value 
Age at Time of 
PEG-ASP Dose 
(years) 
Mean (SD) 
5.5 (3.5) 15.9 (3.2) <0.0001 
BSA at Time of 
PEG-ASP Dose 
(m2) 
Mean (SD) 
0.8 (0.3) 2.0 (0.4) <0.0001 
Sex  
Male count (%) 
89 (56.0) 15 (62.5) 0.66 
Obesity at baseline 
count (%) 
1 (0.6) 4 (16.7) 0.001 
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TABLE 2 PEG-ASP Treatment Related Toxicities  
 ≤3,750 IU PEG-
ASP 
N=159 
>3,750 IU PEG-
ASP 
N=24 
P-value 
PE  
N (%) 
1 (0.6) 1 (4.2) 0.25 
VTE 
N (%) 
3 (1.9) 5 (20.8) 0.001 
Pancreatitis  
N (%) 
3 (1.9) 3 (12.5) 0.03 
Hypersensitivity  
N (%) 
12 (7.6) 1 (4.2) 1.00 
Hyperglycemia  
N (%) 
10 (6.3) 6 (25.0) 0.009 
PE= pulmonary embolism, VTE=venous thromboembolism 
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TABLE 3 Types of VTE 
Patient 
Identification 
Number 
PEG-
ASP  
Dose 
(IU) 
Date of PEG-
ASP Dose 
Immediately 
Preceding VTE 
Number of Days 
from PEG-ASP 
Dose to VTE 
Location of VTE 
Line-
Associated 
VTE  
17 5,700 10/27/2014 5 
Venous superior sagittal sinus 
thrombosis No 
47 2,500 5/3/2013 12 
Venous superior sagittal sinus 
thrombosis No 
68 4,000 6/24/2013 18 Left branch portal vein thrombosis No 
69 
4,600; 
4,775 
10/02/2007; 
2/25/2008 
35; 
25 
Left basilic vein;  
Right basilic vein Yes 
111 4,050 6/10/2008 17 Parietal venous thrombus No 
140 4,250 1/27/2010 19 Transverse venous sinus thrombosis No 
176 2,850 10/30/2009 18 
Intracardiac superior vena cava 
thrombus  Yes 
186 2,800 12/14/2011 12 Cavernous sinus thrombosis No 
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TABLE 4 Effect of PEG-ASP Dosing on Routine Laboratory Values 
  ≤3,750 IU PEG-ASP 
(N = 159) 
>3,750 IU PEG-ASP 
(N = 24) 
P-value 
Amylase 
(U/L) 
N 
Mean (sd) 
Median (Min, 
Max) 
56 
72.5 (110.3) 
38 (30, 639) 
13 
91.9 (69.0) 
67 (30, 267) 
0.013 
Lipase 
(U/L) 
N 
Mean (sd) 
Median (Min, 
Max) 
61 
272.2 (823.1) 
72 (18, 6312) 
17 
686.4 (1383.2) 
171 (13, 5307) 
0.049 
Triglycerides 
(mg/dL) 
N 
Mean (sd) 
Median (Min, 
Max) 
8 
1,004.8 (1,413.7) 
270 (70, 3,900) 
5 
639.2 (830.2) 
179 (0, 1,911) 
0.510 
Platelets 
(109/L) 
N 
Mean (sd) 
Median (Min, 
Max) 
40 
23.1 (45.5) 
13.8 (8, 300) 
17 
14.6 (2.8) 
14.1 (10.5, 19.1) 
0.937 
Fibrinogen N 27 14 0.196 
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(mg/dL) Mean (sd) 
Median (Min, 
Max) 
178.7 (132.6) 
136 (40, 565) 
131.4 (107.3) 
114 (40, 429) 
D-Dimer 
(ng/mL) 
N 
Mean (sd) 
Median (Min, 
Max) 
26 
2,012.4 (3276.2) 
523.5(150, 14696) 
16 
1,658.8 (1978.0) 
733 (305, 7704) 
0.429 
T-Bili 
(g/dL) 
N 
Mean (sd) 
Median (Min, 
Max) 
156 
1.1 (1.5) 
0.8 (0.10, 15.1) 
24 
2.8 (2.5) 
2.15 (0.5, 9.8) 
<0.0001 
D-Bili 
(g/dL) 
N 
Mean (sd) 
Median (Min, 
Max) 
111 
0.4 (1.3) 
0.2 (0.1, 11.3) 
17 
1.9 (2.8) 
0.6 (0.1, 9.0) 
<0.0001 
AST 
(U/L) 
N 
Mean (sd) 
Median (Min, 
Max) 
149 
144.0 (509.7) 
67 (20, 6228) 
24 
162.3 (207.8) 
108.5 (12, 889) 
0.169 
ALT N 156 24 0.018 
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(U/L) Mean (sd) 
Median (Min, 
Max) 
181.3 (260.6) 
117.5 (29, 2712) 
310.7 (347.3) 
180.5 (25, 1517) 
ALP 
(U/L) 
N 
Mean (sd) 
Median (Min, 
Max) 
146 
240.0 (108.2) 
217.5 (13.0, 680) 
24 
240.6 (134.7) 
216.5 (88, 714) 
0.690 
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TABLE 5 Treatment Delays 
Dose Treatment Delay  
(n) 
Proportion P-value 
 No Yes   
≤ 3,750 IU PEG-ASP 321 124 0.28 0.06 
> 3,750 IU PEG-ASP 68 41 0.38 
 
